Tessa S Groen-van Schooten, Micaela Harrasser, Jens Seidel, Emma N Bos, Tania Fleitas, Monique van Mourik, Roos E Pouw, Ruben S A Goedegebuure, Benthe H Doeve, Jasper Sanders, Joris Bos, Mark I van Berge Henegouwen, Victor L J L Thijssen, Nicole C T van Grieken, Hanneke W M van Laarhoven, Tanja D de Gruijl, Sarah Derks
BACKGROUND: Tumors in the distal esophagus (EAC), gastro-esophageal junction including cardia (GEJAC), and stomach (GAC) develop in close proximity and show strong similarities on a molecular and cellular level. However, recent clinical data showed that the effectiveness of chemo-immunotherapy is limited to a subset of GEAC patients and that EACs and GEJACs generally benefit less from checkpoint inhibition compared to GACs. As the composition of the tumor immune microenvironment drives response to (immuno)therapy we here performed a detailed immune analysis of a large series of GEACs to facilitate the development of a more individualized immunomodulatory strategy...
2024: Frontiers in Immunology